GlassScriptPhysician profile
Barbara C O Brien
NPI 1972555696
$18,630.29
in general payments reported to CMS, 2019-2025
68 companies · $3,180 in 2025
The $3,180 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,478 · 2020: $1,671 · 2021: $2,191 · 2022: $2,924 · 2023: $3,256 · 2024: $2,932 · 2025: $3,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,952 · Education: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,951.88 |
| Education | $416.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,965.01 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,677.42 | 2019-2025 | |
| Emd Serono, INC. | $907.85 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $858.40 | 2019-2025 | Austedo Xr, Austedo Xr |
| Pfizer INC. | $770.77 | 2019-2025 | |
| Genentech USA, INC. | $767.40 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Amgen INC. | $664.28 | 2019-2025 | Aimovig, Uplizna |
| Ucb, INC. | $624.59 | 2021-2025 | Nayzilam, Rystiggo, Briviact |
| Alexion Pharmaceuticals, INC. | $600.86 | 2019-2024 | Ultomiris |
| Biogen, INC. | $570.73 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Celgene Corporation | $564.49 | 2021-2025 | Zeposia |
| Argenx US, INC. | $466.31 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $445.74 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Mdd US Operations, LLC | $416.55 | 2019-2025 | Apokyn, Gocovri |
| Lundbeck LLC | $411.20 | 2019-2025 | Vyepti |
Show all 65 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara O Brien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.